Pipeline

July 22, 2019
Company Drug/Device Medical Condition Status
Compass Therapeutics CTX-471 metastatic or locally advanced solid cancers Phase 1 trial initiated
Cyxone T20K multiple sclerosis (MS) Phase 1 trial initiated
SOTIO SO-C101 advanced/metastatic solid tumors Phase 1/1b trial initiated
TARIS Bio TAR-200 in combination with Opdivo (nivolumab) muscle-invasive bladder cancer (MIBC) Phase 1b trial initiated enrolling 25 subjects with MIBC who are scheduled for radical cystectomy
Metacrine, Inc. MET409 non-alcoholic steatohepatitis (NASH) Phase 1b trial initiated
IDEAYA Biosciences, Inc.o IDE196 solid tumors that harbor GNAQ/11 mutations or PRKC fusions Phase 1/2 trial initiated
Trovagene, Inc. onvansertib in combination with FOLFIRI and Avastin (bevacizumab) metastatic colorectal cancer (mCRC) with a KRAS mutation (NCT03829410) Phase 1b/2 trial initiated
EIP Pharma, Inc. neflamapimod Huntington's disease Phase 2 trial initiated enrolling 16 subjects at a site in Cambridge UK
Cara Therapeutics, Inc. Oral KORSUVA (CR845/difelikefalin) pruritus in subjects with atopic dermatitis (AD) Phase 2 trial initiated enrolling 240 adult subjects with AD
Dilafor AB tafoxiparin pregnant women planned for labor induction Phase 2b trial initiated
NeuroRx, Inc. NRX-101 Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB) Phase 2b/3 trial initiated enrolling 140 subjects with Severe Bipolar Depression and ASIB who are stabilized following a single IV infusion of ketamine JPS Health Network in Fort Worth, Texas
Mirum Pharmaceuticals maralixibat progressive familial intrahepatic cholestasis (PFIC) in pediatric subjects Phase 3 trial initiated enrolling 30 subjects with residual BSEP function (PFIC2 non-truncating) aged one to 17 years
CStone Pharmaceuticals avapritinib gastrointestinal stromal tumors (GIST) Phase 3 trial initiated
Sensorion SENS-401 Sudden Sensorineural Hearing Loss (or SSNHL) IND approval granted by the FDA
Karyopharm Therapeutics selinexor in combination with dexamethasone relapsed refractory multiple myeloma in subjects who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody Approval granted by the FDA
ConTIPI Medical, Ltd. ProVate pelvic prolapse in women Approval granted by the FDA
Azurity Pharmaceuticals Katerzia (amlodipine) Oral Suspension, 1 mg/mL hypertension (high blood pressure) in adults and pediatric patients six years of age and older and coronary artery disease in adults Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here